Abstract: A tape containing an unbalanced woven fabric and an adhesive. The woven fabric has a warp dominant face and a filling dominant face, a plurality of warp yarns in a warp direction, and a plurality of filling yarns in a filling direction perpendicular to the warp direction crossing with the warp yarns at a plurality of intersections. At least 55% by number of the intersections have the warp yarn crossing with the filling yarn such that the warp yarn is on the warp dominant face of the fabric. At least 55% by number of the intersections have the warp yarn crossing with the filling yarn such that the filling yarn is on the filling dominant face of the fabric. The warp yarns have a linear mass density of between about 30 and 100 denier and the filling yarns have a linear mass density of between about 70 and 600 denier.

Abstract: A pressurised filtration vessel, for example in cylindrical form, may include a filter element comprising a plurality of filtration membrane modules, e.g., ultrafiltration membrane modules; a distributor connected to an inlet for distributing an input fluid to the filter element; and a collector connected to an outlet for collecting an output fluid from the filter element. The filter element may be located between the distributor and the collector.

Abstract: Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein Q is R1 is cycloalkyl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, —OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as vascular disease and autoimmune diseases.

Abstract: Disclosed are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: n is zero or an integer selected from 1 through 4; R1 is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, benzyl, —OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein Q is R1 is alkyl or aryl, said aryl optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, —OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: Embodiments of the invention relate to the automatic ordering of replacement parts in product servicing. One aspect of the invention concerns a service system including multiple components, a service initiator for identifying a component in the system that has failed or does not operate according to a service threshold, and determining whether the identified component needs a replacement part based on the service threshold. The service system automatically orders a replacement part if the replacement part is needed and notifies a user of the part order. The service threshold may be dynamically adjusted.

Abstract: The present invention provides for tricyclic compounds having the formula (I), wherein R1, R2, R5, R6, R7, and R8 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

Abstract: Disclosed are compounds of Formula (I) or stereoisomers or salts thereof, wherein: X1, X2, X3, W, Q1, Q2, and G2 are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein Q is R1 is cycloalkyl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, —OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as vascular disease and autoimmune diseases.

Abstract: Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein Q is R1 is alkyl or aryl, said aryl optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, —OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: Disclosed are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: n is zero or an integer selected from 1 through 4; R1 is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, benzyl, —OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: Embodiments of machines, systems, computer-implemented methods, and computer program products certify oil and gas well equipment. Embodiments identify a selected well equipment device, a device test specification, and testing sequences to be performed by a corresponding testing apparatus. Embodiments select a testing sequence responsive to the selected device. Embodiments control the testing apparatus for the selected testing sequence so that the corresponding testing apparatus performs the sequence responsive to the device test specification. Embodiments generate testing data for the selected testing sequence and link the testing data for the selected testing sequence to the device identifier for the device so that a certificate can be generated. Embodiments generate a certificate for the selected device responsive to the testing sequences having been performed upon the selected device and link the certificate for the selected device to the device identifier so that the certificate can be readily recalled.

Abstract: An improved ocean wave energy extraction system is disclosed. The system includes at least one duct for receiving an oscillating water column. The duct has a first segment, a second segment arranged transversely to the first segment and a flow control segment intermediate the first and second segments. The flow control segment is configured to inhibit turbulent flow of the oscillating water column flowing within the duct. A turbine is in fluid communication with the second segment of the duct such that the turbine is driven by the fluid flow which is generated by the oscillations of the oscillating water column within the duct. The turbine rotates an electric generator to thereby generate electrical energy.

Abstract: The present invention provides for tricyclic compounds having the formula (I), wherein R1, R2, R5, R6, R7, and R8 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

Abstract: The present invention provides for tricyclic compounds having the formula (I), wherein R1, R2, R5, R6, R7, and R8 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

Abstract: A bag house filtration system in which the filter media includes a woven textile formed from glass yarns other high temperature resistant yarns. A first bath is applied to the textile which contains a conductive component, a first fluoropolymer and a lubricant (in some cases where the yarns are glass). A second bath containing primarily a second fluoropolymer is then applied to the textile and the first composition to seal the first composition on the textile. The textile, so treated dissipates the static electricity normally generated in the filter media thus reducing excessive buildup of contaminating particles and enhancing cleaning of the bag during use.

Abstract: A method and system for controlling fuel in a gas turbine engine including a fuel supply system channeling fuel to a combustor are provided. The system includes a first heat exchanger configured to transfer heat between a working fluid and a first cooling medium. The system also includes a second heat exchanger in series flow communication with the first heat exchanger wherein the second heat exchanger is configured to transfer heat between the working fluid and a second cooling medium. The system further includes a modulating valve configured to control the flow of at least one of the first and the second cooling media to maintain a temperature of the first or second cooling medium substantially equal to a predetermined limit.